Ponce-de-León, Samuel
Torres, Martha
Soto-Ramírez, Luis Enrique
Calva, Juan José
Santillán-Doherty, Patricio http://orcid.org/0000-0002-1782-2073
Carranza-Salazar, Dora Eugenia
Carreño, Juan Manuel http://orcid.org/0000-0002-9039-9275
Carranza, Claudia
Juárez, Esmeralda
Carreto-Binaghi, Laura E. http://orcid.org/0000-0003-0356-4138
Ramírez-Martínez, Luis
Paz De la Rosa, Georgina http://orcid.org/0000-0002-0491-9271
Vigueras-Moreno, Rosalía
Ortiz-Stern, Alejandro http://orcid.org/0000-0002-4468-4817
López-Vidal, Yolanda http://orcid.org/0000-0001-7111-8813
Macías, Alejandro E. http://orcid.org/0000-0002-6573-4350
Torres-Flores, Jesús
Rojas-Martínez, Oscar
Suárez-Martínez, Alejandro
Peralta-Sánchez, Gustavo
Kawabata, Hisaaki
González-Domínguez, Irene
Martínez-Guevara, José Luis
Sun, Weina http://orcid.org/0000-0002-2435-5047
Sarfati-Mizrahi, David
Soto-Priante, Ernesto
Chagoya-Cortés, Héctor Elías http://orcid.org/0009-0006-2786-4724
López-Macías, Constantino http://orcid.org/0000-0003-0530-492X
Castro-Peralta, Felipa http://orcid.org/0000-0003-3982-6259
Palese, Peter http://orcid.org/0000-0002-0337-5823
García-Sastre, Adolfo http://orcid.org/0000-0002-6551-1827
Krammer, Florian http://orcid.org/0000-0003-4121-776X
Lozano-Dubernard, Bernardo http://orcid.org/0009-0009-6430-7080
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (75N93019C00051, 75N93021C00014, 75N93021C00014, AI097092-07, AI145870-03, 75N93019C00051)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
The Mexican Government supports Patria via CONACYT.
Article History
Received: 12 February 2022
Accepted: 14 April 2023
First Online: 10 May 2023
Competing interests
: P.P. reports financial support from the U.S. NIAID (Centers of Excellence for Influenza Research and Response 75N93021C00014, P01 AI097092-07, R01 AI145870-03). A.G.S. reports financial support from the U.S. NIAID (Centers of Excellence for Influenza Research and Response 75N93021C00014, Collaborative Influenza Vaccine Innovation Centers contract 75N93019C00051). F.K. reports financial support from the U.S. NIAID (Collaborative Influenza Vaccine Innovation Centers contract 75N93019C00051, Center of Excellence for Influenza Research and Surveillance contract HHSN272201400008C), the JPB Foundation, and the Open Philanthropy Project (research grant 2020-215611, 5384), and the U.S. NCI (contract 75N91019D00024, task order 75N91020F00003); he also has received royalties (Avimex), consulting fees (Pfizer, Seqirus, Third Rock Ventures, and Avimex), and payment for academic lectures during the past two years. The NDV construct administered in this study was developed by faculty members at the Icahn School of Medicine at Mount, including W.S., P.P., A.G.S., and F.K. Mount Sinai has filed patent applications related to SARS-CoV-2 serological assays and the NDV-based SARS-CoV-2 vaccines; the institution and its faculty inventors could benefit financially. The live vaccine used in the study was developed by members of Avimex and Avimex filed patent applications with Mount Sinai and CONACYT. M.T., D.S.-M., E.S.P., C.R.L.-M., H.E.C.-C., F.C.-P., G.P.-D.L.R., and B.L.-D. are named as inventors on at least one of those patent applications. The clinical study was entirely performed in Mexico. Mount Sinai had no role in the clinical study and only access to data required to generate figures and write the manuscript. The rest of the participants are employees of their corresponding institutions. S.P.d.L., J.J.C., P.S.-D., Y.L.-V., and A.M. contributed to this study pro bono and declare no competing interests.